EQUI-HIPPO: Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05755295
Collaborator
(none)
15
1
35.8

Study Details

Study Description

Brief Summary

On average, each year in the former region, 60 new patients under the age of 18 are treated for a brain tumor, with an active post-treatment follow-up file of 350 patients. Because of the significant sequelae induced by the disease or the treatments, these patients will very often require rehabilitative care.

The interest of involving the horse in the population of patients cured of a medulloblastoma but with important physical and psychological after-effects is to be able to combine a therapy using animal mediation (equitherapy) and a rehabilitation therapy based on the three-dimensional movement of the horse (hippotherapy).

Condition or Disease Intervention/Treatment Phase
  • Other: horse therapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Pilot Study Evaluating Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma and Describing the Evolution of Their Physical and Psychological Characteristics
Anticipated Study Start Date :
Mar 8, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: horse therapy

Other: horse therapy
equitherapy and hippotherapy once a week during 16 weeks

Outcome Measures

Primary Outcome Measures

  1. number of sessions performed [16 weeks]

    number of sessions equitherapy and hippotherapy performed

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years to 26 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • complete remission of medulloblastoma and after 5 years of the end of treatment

  • living within 30 km away the riding center and/or less than 1 hour of transport

  • informed consent

Exclusion Criteria:
  • Landsky score below 50% for minors until 16 years old and Karnofsky score below 50% for patients over 16 years

  • major under juridical protection

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Anne-Isabelle BERTOZZI, MD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT05755295
Other Study ID Numbers:
  • RC31/22/0218
First Posted:
Mar 6, 2023
Last Update Posted:
Mar 6, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 6, 2023